🎤 Upcoming Biotech Conferences
Loading conferences...
Free public preview
Track cancer catalysts with approval-probability scores and free alerts.
Oncology Biotech Pipeline: Cancer Drugs in Clinical Development
Every cancer program BioRadar tracks across 14 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 354 cancer drug programs across 14 public companies, with 1 upcoming FDA decision in this area. The most active companies by program count are IBRX, GILD, ACHV, CORT, ORIC.
354Drug programs
14Companies
94In Phase 3
1Upcoming FDA dates
Upcoming FDA decisions in Oncology (Cancer)
| Date | Ticker | Drug / Indication | Type | In |
|---|---|---|---|---|
| Dec 23, 2026 | GILD | Multiple Myeloma &ndash | BLA | 152d |
Companies with cancer programs
Phase 3 oncology (cancer) programs (94)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Docetaxel | Castrate-Resistant Prostate Cancer |
| ACHV | Custirsen | Non-Small Cell Lung Cancer |
| ACHV | Prednisone | Prostate Cancer |
| ACHV | Dexamethasone | Prostate Cancer |
| ACHV | cabazitaxel | Prostate Cancer |
| ACHV | custirsen sodium | Prostate Cancer |
| ACHV | isotonic, 0.9% sodium chloride | Castrate-Resistant Prostate Cancer |
| ACHV | TOCOSOL Paclitaxel | Breast Neoplasm |
| ACHV | Taxol | Breast Neoplasm |
| ARVN | ARV-471 | Advanced Breast Cancer |
| ARVN | Fulvestrant | Advanced Breast Cancer |
| ARVN | Letrozole | Breast Cancer |
| ARVN | Vepdegestrant (ARV-471/PF-07850327) | Breast Cancer |
| CADL | Pembrolizumab | Non-squamous, Non-Small Cell Lung Cancer |
| CADL | Docetaxel | Non-squamous, Non-Small Cell Lung Cancer |
| CORT | Relacorilant 150 mg once daily (QD) | Ovarian Neoplasm |
| CORT | Nab-paclitaxel 100 mg/m^2 | Ovarian Neoplasm |
| CORT | Nab-paclitaxel 80 mg/m^2 | Ovarian Neoplasm |
| CORT | Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma |
| CORT | Relacorilant, 100 mg and 25 mg | Metastatic Pancreatic Ductal Adenocarcinoma |
| GILD | Cyclophosphamide | Multiple Myeloma |
| GILD | KITE-753 | Relapsed or Refractory Large B-cell Lymphoma |
| GILD | Fludarabine | Multiple Myeloma |
| GILD | Zimberelimab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Domvanalimab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Nivolumab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Axicabtagene Ciloleucel | Relapsed or Refractory Large B-cell Lymphoma |
| GILD | Capecitabine | Triple Negative Breast Cancer |
| GILD | Prednisone | High-risk Large B-cell Lymphoma (LBCL) |
| GILD | Rituximab | High-risk Large B-cell Lymphoma (LBCL) |
| GILD | Doxorubicin | High-risk Large B-cell Lymphoma (LBCL) |
| GILD | Vincristine | High-risk Large B-cell Lymphoma (LBCL) |
| GILD | Etoposide | High-risk Large B-cell Lymphoma (LBCL) |
| GILD | Fluorouracil | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Oxaliplatin | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Leucovorin | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Pomalidomide | Multiple Myeloma |
| GILD | Bortezomib | Multiple Myeloma |
| GILD | Carfilzomib | Multiple Myeloma |
| GILD | Dexamethasone | Multiple Myeloma |
Phase 2 oncology (cancer) programs (109)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Abiraterone Acetate | Prostate Cancer |
| ACHV | OGX-427 | Prostate Cancer |
| ACHV | Carboplatin | Squamous Cell Lung Cancer |
| ACHV | Apatorsen (OGX-427) | Squamous Cell Lung Cancer |
| ACHV | Gemcitabine | Squamous Cell Lung Cancer |
| ACHV | OGX-427 600 mg | Urologic Neoplasms |
| ACHV | OGX-427 1000 mg | Urologic Neoplasms |
| ACHV | Cisplatin | Urologic Neoplasms |
| ACHV | custirsen (OGX-011)/docetaxel | Prostate Cancer |
| ACHV | custirsen (OGX-011)/mitoxantrone | Prostate Cancer |
| ACHV | S-8184 Paclitaxel Injectable Emulsion | Carcinoma, Non-Small-Cell Lung |
| ACHV | TOCOSOL(R) Paclitaxel | Breast Cancer |
| ACHV | Experimental Arm: TOCOSOL Paclitaxel | Urologic Neoplasms |
| ACRV | ACR-368 | Head and Neck Squamous Cell Carcinoma |
| ACRV | Gemcitabine | Head and Neck Squamous Cell Carcinoma |
| AIM | Rintatolimod | Prostate Adenocarcinoma |
| AIM | Recombinant Interferon Alfa-2b | Prostate Adenocarcinoma |
| AIM | EC Aspirin | Prostate Adenocarcinoma |
| AIM | Pembrolizumab | Ovarian Cancer |
| AIM | Cisplatin | Ovarian Cancer |
| AIM | Celecoxib | Ovarian Cancer |
| AIM | αDC1 Vaccine | Ovarian Cancer |
| AIM | Bioferon | Ovarian Cancer |
| AIM | Paclitaxel | Ovarian Cancer |
| ARTV | AB-101 | Relapsed or Refractory Hodgkin Lymphoma |
| ARTV | Cyclophosphamide | Relapsed or Refractory Hodgkin Lymphoma |
| ARTV | Fludarabine | Relapsed or Refractory Hodgkin Lymphoma |
| ARTV | AFM13 | Relapsed or Refractory Hodgkin Lymphoma |
| ARTV | Interleukin-2 | Relapsed or Refractory Hodgkin Lymphoma |
| ARVN | Anastrozole | Breast Cancer |
| BHVN | Ipilimumab | Melanoma |
| BHVN | Nivolumab | Melanoma |
| CADL | Aglatimagene besadenovec + valacyclovir | Prostate Cancer Patients Treated by Radiotherapy |
| CADL | Aglatimagene besadenovec | Prostate Cancer |
| CADL | valacyclovir | Prostate Cancer |
| CADL | Temozolomide | Malignant Glioma |
| CADL | CAN-2409 | Malignant Glioma |
| CORT | Enzalutamide | Metastatic Breast Cancer |
| CORT | Gemcitabine 1000 mg/m^2 | Adenocarcinoma |
| CORT | Bevacizumab 10 mg/kg | Ovarian Cancer |
Phase 1 oncology (cancer) programs (148)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Custirsen, paclitaxel and carboplatin | Cancer |
| ACHV | SN2310 Injectable Emulsion | Breast Neoplasms |
| ACRV | ACR-2316 | Specific Advanced Solid Tumors |
| AIM | Cisplatin + celecoxib + DC vaccine | Cancer of Ovary |
| AIM | Cisplatin + CKM + Celecoxib + DC Vaccine | Cancer of Ovary |
| AIM | Durvalumab | Metastatic Pancreatic Cancer |
| AIM | Chemokin Modulatory Regimen (5 MU/m2) | Colorectal Cancer |
| AIM | Chemokin Modulatory Regimen (20 MU/m2) | Colorectal Cancer |
| AIM | Chemokin Modulatory Regimen (10 MU/m2) | Colorectal Cancer |
| ARTV | AB-201 | Breast Cancer |
| ARTV | Bendamustine | Non Hodgkin Lymphoma |
| ARTV | GCC2005 | Lymphoma, T-Cell |
| ARVN | Samuraciclib | Breast Cancer |
| ARVN | Abiraterone | Prostate Cancer Metastatic |
| ARVN | Bavdegalutamide | Prostate Cancer Metastatic |
| ARVN | ARV-471 in combination with palbociclib | Breast Cancer |
| ARVN | Ribociclib | Breast Cancer |
| ARVN | PF-07220060 | Breast Cancer |
| ARVN | ARV-393 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgki |
| ARVN | Glofitamab | Relapsed/Refractory (R/R) Mature B Cell Non Hodgki |
| ARVN | Abemaciclib | Breast Cancer |
| ARVN | ARV-471 in combination with Everolimus | Breast Cancer |
| ARVN | ARV-110 | Prostate Cancer Metastatic |
| BHVN | Cemiplimab | Solid Tumor |
| BHVN | BHV-1510 | Solid Tumor |
| BHVN | BHV-1530 | Solid Tumor |
| CADL | rQNestin | Malignant Glioma of Brain |
| CADL | Cyclophosphamide | Malignant Glioma of Brain |
| CADL | CAN-2409 + valacyclovir | Lung Cancer |
| CADL | Nivolumab | Glioma, Malignant |
| CADL | AdV-tk | Glioma, Malignant |
| CORT | Exicorilant | Metastatic Castration-Resistant Prostate Cancer |
| CORT | Nenocorilant 300 mg | Neoplasms |
| CORT | Nenocorilant 200 mg | Neoplasms |
| CORT | Nenocorilant 400 mg | Neoplasms |
| CORT | Nivolumab | Neoplasms |
| CORT | Pembrolizumab | Adrenocortical Carcinoma |
| CORT | Relacorilant with nab-paclitaxel | Solid Tumors |
| GILD | nab-Paclitaxel | Metastatic Breast Cancer |
| GILD | Sacituzumab Govitecan-hziy | Advanced Solid Tumor |
Track cancer catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a cancer watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →